Home/ Stocks/ TOVX

Theriva Biologics, Inc.

TOVX XASE

$0.35 -0.01 (-1.67%) ▼ 15-min delayed

Open

$0.36

High

$0.36

Low

$0.34

Volume

1.24M

Market Cap

$16.25M

About Theriva Biologics, Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 16 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$300.0K	$-2,044,000	$-0.05
FY 2025	$0	$-23,739,000	$-2.08
Q3 2025	$0	$-4,361,000	$-0.45
Q2 2025	$0	$-13,058,000	$-1.93

Related Market News

No specific coverage for TOVX yet. Check out our latest market news or earnings calendar.

Get TOVX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Theriva Biologics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.